Company intelligence / Profile preview

RevImmune

Bethesda, Maryland, United Statesrevimmune.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

CYT107 has been administered to over 500 patients with diverse infectious diseases, sepsis, and cancers, demonstrating an excellent safety profile and promising results. The therapy is designed to restore lymphocyte function and increase lymphocyte proliferation to aid in eliminating invading pathogens. Early success was shown in COVID-19 patients, where CYT107 improved absolute lymphocyte counts.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Recombinant human Interleukin-7 (CYT107)
Industry: Biotech

Drug pipeline

2 assets

recombinant human interleukin-7

1 more asset in the full pipeline.

Request access →

Partnerships

INITS (for CMC, regulatory affairs, quality management, and IMP management)

Beyond the preview

Go deeper on RevImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevImmune.

Explore the full profile